The business intelligence firm, led by Michael Saylor, continued its Bitcoin acquisition strategy with a modest $75.3 million purchase last week, bringing its total holdings to 713,502 BTC. Despite a recent price correction, the company's average purchase price remains below current market levels.
The Vatican has launched a meticulous three-month restoration of Michelangelo's iconic 'Last Judgment' fresco in the Sistine Chapel, aiming to revive the masterpiece's original chromatic brilliance obscured by decades of grime.
A suspected human smuggler with a prior conviction was shot by federal agents near the Arizona-Mexico border after allegedly firing at a CBP helicopter and agents during a foot pursuit, according to law enforcement officials.
A federal appeals court has dismissed a Justice Department misconduct complaint against U.S. District Judge James Boasberg, ruling the government failed to substantiate its allegations regarding the judge's public comments.
Analysts maintain a bullish outlook on Goodyear Tire & Rubber, citing strong potential in the replacement tire market and favorable inventory trends, with a median price target suggesting a 7% upside.
Despite a recent sales miss, AutoZone (AZO) is doubling down on store growth, drawing mixed analyst reactions. JPMorgan remains bullish with an $4,100 price target, while Wolfe Research downgraded the stock, highlighting the complex landscape for the auto parts retailer.
H.C. Wainwright and Chardan Capital upgrade Korro Bio (KRRO) to Buy, citing the independent potential of its RNA-editing asset KRRO-121 and strong preclinical data as key catalysts.
Disney CEO Bob Iger confirmed that AI-generated videos from OpenAI's Sora will begin appearing on Disney+ within months, framing the move as an additive feature for short-form content while downplaying any ripple effects on the company's traditional film and TV pipeline.
Google is rolling out a significant update to its Chrome browser, embedding advanced Gemini AI capabilities directly into the user interface. The move signals a strategic push to make AI a central, everyday tool for web navigation and tasks.
While reports surface of potential delays for AMD's next-generation MI450 AI accelerators, major analysts reaffirm bullish price targets, highlighting strong long-term demand and the stock's 100% surge over the past year.
ARK Invest's Cathie Wood has aggressively added to her position in Broadcom (AVGO) this month, signaling strong conviction in the chipmaker's AI and datacenter prospects despite recent share price weakness, as analysts also turn bullish on the stock's long-term trajectory.
With gold and silver hitting record highs amid market turbulence, numismatic experts argue that certified rare coins offer a unique blend of tangible value, historical significance, and surprising liquidity for discerning investors.
As XRP hovers around $2, a stark divide emerges between institutional and algorithmic forecasts for its 2026 value. Standard Chartered's bullish $8 target contrasts with more cautious AI projections, with the outcome likely hinging on ETF inflows, regulatory clarity, and real-world adoption.
A new study highlights a persistent gap between finance and cybersecurity leaders on strategic alignment, risk measurement, and investment priorities, despite widespread recognition of cyber threats.
Canadian junior miner G2 Goldfields Inc. (TSX: GTWO), despite recent losses, is projected by analysts to reach profitability within two years, backed by aggressive growth forecasts and a debt-free balance sheet.
A new report highlights how small and medium-sized businesses are leveraging AI, hyper-personalization, and sustainable practices not just to adapt, but to lead in a rapidly evolving marketplace.
Ardelyx, Inc. (NASDAQ: ARDX) has received significant analyst upgrades, with TD Cowen and Jefferies raising price targets ahead of the company's fourth-quarter results. The optimism centers on the commercial trajectory of its flagship drug, tenapanor, for gastrointestinal and kidney conditions.
Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.
Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.
Goldman Sachs has downgraded MoonLake Immunotherapeutics (MLTX) to Sell, highlighting the failed VELA-2 trial endpoint and persistent approval risks for its key drug, sonelokimab, despite a competing firm's more bullish outlook.
